Imexon (INN, trade name Amplimexon) is a substance that is being studied in the treatment of some types of cancer, including pancreatic, lung, breast, prostate, melanoma, and multiple myeloma. It is a cyanoaziridine derivative.
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider |
|
| UNII | |
| KEGG |
|
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.056.199  |
| Chemical and physical data | |
| Formula | C4H5N3O |
| Molar mass | 111.104 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
This article incorporates public domain material from Dictionary of Cancer Terms. U.S. National Cancer Institute.
 | This antineoplasticorimmunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |